Paul Nouri, CFP
Hedge fund manager, long/short equity, healthcare

Enzo Investors Have To Be In It For The Long Haul

Since I wrote last summer that Enzo Biochem (NYSE:ENZ) made an attractive investment opportunity in light of recent M&A in the space, the stock is up 35%, respectable, but not what I had in mind.

(click to enlarge)

Since then, the company has reported four quarters of results. While the clinical lab business, which I called out as their most attractive asset, has performed alright, the products business has declined in every consecutive quarter.

Starting with the clinical lab, sales in 3 of the past 4 quarters have been encouraging. In the latest quarter reported, the company's results suffered from the effects of Hurricane Sandy, however, even excluding the hurricane, it appears revenues would have declined slightly year...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details